[en] SGLT2 inhibitors (gliflozins) have proven their efficacy in reducing complications due to atherosclerotic cardiovascular disease, heart failure and chronic kidney disease both in placebo-controlled clinical trials and in real-life studies versus other glucose-lowering agents (except GLP-1 analogues) in patients with type 2 diabetes. Hence, observational studies demonstrate that they are poorly used in -clinical practice, including in patients at high cardiorenal risk. -Reasons are multiple and involve physicians, patients and health care system with restricted criteria for prescription and reimbursement in many countries. Bridging the gap between scientific proves from evidence-based medicine and clinical practice represents a major health-care issue.
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Bibliography
Scheen AJ. Sodium-glucose co-transporter type 2 inhibitors for the treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2020 Oct;16(10):556-77.
Braunwald E. Gliflozins in the Management of Cardiovascular Disease. N Engl J Med. 2022 May 26;386(21):2024-34.
Li CX, Liang S, Gao L, Liu H. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis. PLoS One. 2021 Feb 19;16(2):e0244689.
Scheen AJ. Place des inhibiteurs des SGLT2 dans le traitement du patient diabétique de type 2. Med Mal Metab. 2018 Feb;12(1):22-30.
Davies MJ, Aroda VR, Collins BS, et al. Management of HYPerglycaemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022 Dec;65(12):1925-66.
Darmon P, Bauduceau B, Bordier L, et al. Prise de position de la Société francophone du diabète (SFD) sur les stratégies d'utilisation des traitements antihyperglycémiants dans le diabète de type 2 - 2023. Med Mal Metab. 2023 Dec;17(8):664-93.
Marx N, Federici M, Schütt K, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023 Oct 14;44(39):4043-140.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024 Apr;105(4S):S117-314.
Scheen AJ. Bridging the gap in cardiovascular care in diabetic patients: are cardioprotective antihyperglycemic agents underutilized? Expert Rev Clin Pharmacol. 2023 Jul- Dec;16(11):1053-62.
Arnold SV, de Lemos JA, Rosenson RS, et al. Use of Guideline-Recommended Risk Reduction Strategies Among Patients With Diabetes and Atherosclerotic Cardiovascular Disease. Circulation. 2019 Aug 13;140(7):618-20.
Eberly LA, Yang L, Eneanya ND, et al. Association of Race/Ethnicity, Gender, and Socioeconomic Status With Sodium-Glucose Cotransporter 2 Inhibitor Use Among Patients With Diabetes in the US. JAMA Netw Open. 2021 Apr 1;4(4):e216139.
Nargesi AA, Jeyashanmugaraja GP, Desai N, et al. Contemporary National Patterns of Eligibility and Use of Novel Cardioprotective Antihyperglycemic Agents in Type 2 Diabetes Mellitus. J Am Heart Assoc. 2021 Jul 6;10(13):e021084.
Mahtta D, Ramsey DJ, Lee MT, et al. Utilization Rates of SGLT2 Inhibitors and GLP-1 Receptor Agonists and Their Facility-Level Variation Among Patients With Atherosclerotic Cardiovascular Disease and type 2 Diabetes: Insights From the Department of Veterans Affairs. Diabetes Care. 2022 Feb 1;45(2):372-80.
Devineni D, Akbarpour M, Gong, Wong ND. Inadequate Use of Newer Treatments and Glycemic Control by Cardiovascular Risk and Sociodemographic Groups in US Adults with Diabetes in the NIH Precision Medicine Initiative All of Us Research Program. Cardiovasc Drugs Ther. 2024 Apr;38(2):347-57.
Hao R, Myroniuk T, McGuckin T, et al. Underuse of cardiorenal protective agents in high-risk diabetes patients in primary care: a cross-sectional study. BMC Prim Care. 2022;23(1):124.
Ozaki AF, Ko DT, Chong A, et al. Prescribing patterns and factors associated with sodium-glucose cotransporter-2 inhibitor prescribing in patients with diabetes mellitus and atherosclerotic cardiovascular disease. CMAJ Open. 2023 Jun 13;11(3):E494-503.
Hussain A, Ramsey D, Lee M, et al. Utilization Rates of SGLT2 Inhibitors Among Patients With Type 2 Diabetes, Heart Failure, and Atherosclerotic Cardiovascular Disease: Insights From the Department of Veterans Affairs. JACC Heart fail. 2023 Aug;11(8 Pt 1):933-42.
Bidulka P, Mathur R, Lugo-Palacios DG, et al. Ethnic and socioeconomic disparities in initiation of second-line antidiabetic treatment for people with type 2 diabetes in England: A cross-sectional study. Diabetes Obes Metab. 2023 Jan;25(1):282-92.
Nanna MG, Kolkailah AA, Page C, Peterson ED, Navar AM. Use of Sodium- Glucose Cotransporter 2 Inhibitors and Glucagonlike Peptide-1 Receptor Agonists in Patients With Diabetes and Cardiovascular Disease in Community Practice. JAMA Cardiol. 2023 Jan 1;8(1):89-95.
Barth SD, Kostev K, Krensel M, Mathey E, Rathmann W. Do Glucagonlike Peptide-1 Receptor Agonist and sodium-glucose Co-transporter 2 Inhibitor Prescriptions in Germany Reflect Recommendations for Type 2 Diabetes with Cardiovascular Disease of the ADA/EASD Consensus Report? Exp Clin Endocrinol Diabetes. 2023 Mar;131(3):153-61.
Dave CV, Schneeweiss S, Wexler DJ, Brill G, Patorno E. Trends in Clinical Characteristics and Prescribing Preferences for SGLT2 Inhibitors and GLP-1 Receptor Agonists, 2013-2018. Diabetes Care. 2020 Apr;43(4):921-4.
Pierce JB, Vaduganathan M, Fonarow GC, et al. Contemporary Use of Sodium-Glucose Cotransporter-2 Inhibitor Therapy Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction in the US: The Get With The Guidelines-Heart Failure Registry. JAMA Cardiol. 2023 Jul 1;8(7):652-61.
Stolfo D, Lund LH, Benson L, et al. Real-world use of sodium-glucose cotransporter 2 inhibitors in patients with heart failure and reduced ejection fraction: Data from the Swedish Heart Failure Registry. Eur J Heart Fail. 2023 Sep;25(9):1648-58.
Bermudez SR, Anderson JR, Bos AJ, Ray GM. Utilization rates and predictors of sodium glucose cotransporter 2 inhibitor use in patients with heart failure with or without type 2 diabetes. Am J Health Syst Pharm. 2023 Dec 5;80(24):1787-95.
Jeong SJ, Lee SE, Shin DH, et al. Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study. BMC Nephrol. 2021 May 14;22(1):177.
Harris ST, Patorno E, Zhuo M, Kim SC, Paik JM. Prescribing Trends of Antidiabetes Medications in Patients With Type 2 Diabetes and Diabetic Kidney Disease, a Cohort Study. Diabetes Care. 2021 Aug 3;44(10):2293-301.
Nicholas SB, Daratha KB, Alicic RZ, et al. Prescription of guideline-directed medical therapies in patients with diabetes and chronic kidney disease from the CURE-CKD Registry, 2019-2020. Diabetes Obes Metab. 2023 Oct;25(10):2970-9.
Lau D, Pannu N, Yeung RO, Scott- Douglas N, Klarenbach S. Use of sodium-glucose cotransporter 2 inhibitors in Alberta adults with chronic kidney disease: a cross-sectional study identifying care gaps to inform knowledge translation. CMAJ Open. 2023 Jan 31;11(1):E101-9.
Zhuo M, Li J, Buckley LF, et al. Prescribing Patterns of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with CKD: A Cross-Sectional Registry Analysis. Kidney360. 2022 Jan 19;3(3):455-64.
Neuen BL, Jun M, Wick J, et al. Estimating the population-level impacts of improved uptake of SGLT2 inhibitors in patients with chronic kidney disease: a cross-sectional observational study using routinely collected Australian primary care data. Lancet Reg Health West Pac. 2024 Dec 18;43:100988.
Scheen AJ. Real-life underuse of SGLT2 inhibitors for patients with type 2 diabetes at high cardiorenal risk. Diabetes Epidemiol Manag. 2024 Jan- Mar;13:100184.
Scheen AJ. Underuse of GLP-1 receptor agonists in the management of type 2 diabetes despite a favourable benefit-safety profile. Expert Opin Drug Saf. 2024 May 13:13:1-4. DOI: 0.1080/14740338.2024.2354885.
Scheen AJ. Underuse of glucose-lowering medications associated with cardiorenal protection in type 2 diabetes: from delayed initiation to untimely discontinuation. Lancet Reg Health Eur. 2023 Mar 30;29:100627.
Scheen AJ. Paradoxical real-life underuse of GLP-1 receptor agonists in type 2 diabetes patients with atherosclerotic cardiovascular disease. Diabetes Epidemiol Manag. 2024 Apr- Jun;14:100197.
Marilly E, Cottin J, Cabrera N, et al. SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefits. Diabetologia. 2022 Dec;65(12):2000-10.
Scheen AJ. An update on the safety of SGLT2 inhibitors. Expert Opin Drug Saf. 2019 Apr;18(4):295-311.
Diévart F, Darmon P, Halimi JM, et al. Quand et comment utiliser les inhibiteurs de la SGLT2 ou gliflozines en pratique clinique ? Un consensus proposé par la Société francophone du diabète (SFD), la Société française de cardiologie (SFC), le Collège national des cardiologues français (CNCF) et la Société francophone de néphrologie, dialyse et transplantation (SFNDT). Nephrol Ther. 2023;19(4):251-77.
Scheen AJ, Paquot N. Combinaison thérapeutique innovante pour le diabète type 2 à risque cardiorénal. Rev Med Suisse. 2024;20:1492-6.
Similar publications
Sorry the service is unavailable at the moment. Please try again later.
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.
